{"prompt": "['Date and version No: FUTUREGB_Protocol_V6.0_19Jan2022.docr', 'Study Title', 'FUTURE-GB - Functional and Ultrasound guided Resection of GlioBlastoma (GB):', 'A two-Stage trial. Stage 1: non-randomised learning Stage evaluation of', 'participating centres (an IDEAL study). Stage 2: a multicentre definitive trial with', '2 mechanistic sub-studies.', 'Internal ref. no. / short title', 'FUTURE-GB', 'Study registration', 'ISRCTN: 38834571', 'Sponsor', 'University of Oxford', 'Funder', 'NIHR EME Programme', 'Study Design', 'FUTURE-GB is a 2-Stage trial: Stage 1 is a non-randomised multicentre learning', 'and evaluation Stage (IDEAL IIB study), and Stage 2 a prospective, multicentre', 'definitive randomised controlled trial.', 'Study Participants', 'Newly diagnosed glioblastoma (GB) patients', 'Sample Size', 'Up to 75 patients will participate in Stage 1, (up to 5 per centre).', '357 patients will participate in the Stage 2, randomised controlled trial', 'Planned Study Period', 'Patients participating in the trial will be followed at 3 monthly intervals up to 24', 'months after randomisation.', 'Planned Recruitment period', '6-9 months Stage 1 and then 27 months for Stage 2.', 'Intervention(s)', 'Surgery to resect the GB using Diffusion Tensor Imaging (DTI) and intraoperative', 'Ultrasound (iUS) (navigated iUS where available) in addition to standard care', '(i.e. neuronavigation based on preoperative MRI and intraoperative use of 5-', 'aminolevulinic acid (5-ALA))', 'Comparator', 'The comparator is standard care as per current NICE guidelines (i.e.', 'neuronavigation based on preoperative MRI and intraoperative use of 5-ALA).', 'Clinical Research Protocol Template version 14.0', 'Page 11 of 65', 'C', 'Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2018', 'CONFIDENTIAL']['Date and version No: FUTUREGB_Protocol_V6.0_19Jan2022.doc', 'Stage 1', 'Objectives', 'Outcome Measures', 'Timepoint(s)', 'Primary', 'To demonstrate the feasibility of using', '1. Operation length', 'Hospital discharge', 'Outcomes', 'DTI and iUS* in addition to standard of', '2. Successful use of DTI', 'and 6 months post-', 'care (neuronavigation based on', 'neuronavigation and', 'op.', 'preoperative MRI and intraoperative', 'iUS* to achieve', 'use of 5-ALA) for neurosurgery (at', 'maximal safe tumour', 'selected UK NHS hospitals).', 'resection without major', 'neurological deficit', '3. Extent of tumour', 'resection assessed on', 'postoperative MRI', 'scan.', '4. Surgical Complication', 'and Serious Adverse', 'Events', 'Stage 2', 'Objectives', 'Outcome Measures', 'Timepoint(s)', 'Primary', 'To assess whether additional', 'Composite of global health', 'To be recorded at', 'Outcomes', 'intraoperative imaging (DTI and iUS*)', 'status domain of the QLQ-', 'baseline; 6wks', 'to standard of care (neuronavigation', 'C30 questionnaire,', 'post-op., 3mths', 'based on preoperative MRI scan and', 'Progression Free Survival', 'post-op., and then', 'intraoperative 5-ALA) improves', '(PFS) and Overall Survival', '3mthly up to 24', 'Deterioration Free Survival (DFS)', '(OS) with an event defined', 'months', '(Where deterioration relates to global', 'as either deterioration,', 'health status only)', 'progression or death.', 'Secondary', 'To assess whether additional', '4 composites using the', 'To be recorded at', 'Outcomes', 'intraoperative imaging (DTI and iUS*)', 'respective domain of QLQ-', 'baseline; 6wks', 'to standard of care (Neuronavigation', 'C30 (physical functioning', 'post-op., 3mths', 'and intraoperative 5-ALA) improves', 'and social functioning) and', 'post-op., and then', 'DFS where deterioration relates to', 'BN20 (motor dysfunction', '3mthly up to 24', 'months', 'physical functioning, social functioning', 'and communication deficit)', 'from the QLQ-C30, and motor', 'combined with PFS and OS.', 'dysfunction and communication deficit', 'Clinical Research Protocol Template version 14.0', 'Page 12 of 65', 'C', 'Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2018', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}